Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India

BACKGROUND: We undertook this study to assess the incremental cost per quality adjusted life year (QALY) gained with the use of pan-genotypic sofosbuvir (SOF) + velpatasvir (VEL) for HCV patients, as compared to the current treatment regimen under the universal free treatment scheme in Punjab state....

Descripción completa

Detalles Bibliográficos
Autores principales: Chugh, Yashika, Dhiman, Radha Krishan, Premkumar, Madhumita, Prinja, Shankar, Singh Grover, Gagandeep, Bahuguna, Pankaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715223/
https://www.ncbi.nlm.nih.gov/pubmed/31465503
http://dx.doi.org/10.1371/journal.pone.0221769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715223/
https://www.ncbi.nlm.nih.gov/pubmed/31465503
http://dx.doi.org/10.1371/journal.pone.0221769

Ejemplares similares